Vical (VICL) Earns News Impact Rating of 0.20
News headlines about Vical (NASDAQ:VICL) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vical earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5974534801976 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s rankings:
- Vical (VICL) Stock Rating Reaffirmed by HC Wainwright (americanbankingnews.com)
- Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis (finance.yahoo.com)
- Analyzing Recro Pharma (REPH) and Vical (VICL) (americanbankingnews.com)
- Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs (finance.yahoo.com)
VICL has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Vical in a research report on Tuesday, November 21st. Zacks Investment Research raised Vical from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Finally, ValuEngine raised Vical from a “strong sell” rating to a “sell” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $7.00.
In related news, major shareholder Armistice Capital Master Fund purchased 100,000 shares of Vical stock in a transaction dated Monday, January 22nd. The stock was purchased at an average cost of $1.43 per share, with a total value of $143,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert C. Merton bought 85,700 shares of Vical stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average cost of $1.75 per share, for a total transaction of $149,975.00. Following the completion of the transaction, the director now directly owns 95,451 shares in the company, valued at $167,039.25. The disclosure for this purchase can be found here. Insiders own 5.98% of the company’s stock.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.